TransMedics Group (NASDAQ:TMDX) Sees Unusually-High Trading Volume – Time to Buy?

TransMedics Group, Inc. (NASDAQ:TMDX) shares saw strong trading volume on Wednesday . 464,930 shares changed hands during mid-day trading, a decline of 49% from the previous session’s volume of 912,090 shares.The stock last traded at $84.17 and had previously closed at $88.50.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Oppenheimer cut their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday. Morgan Stanley raised their price target on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Needham & Company LLC cut their price target on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday. JPMorgan Chase & Co. cut their price target on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Stephens raised their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $144.80.

TransMedics Group Price Performance

The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. The stock has a market cap of $2.79 billion, a PE ratio of 90.30 and a beta of 1.99. The stock’s 50-day moving average is $146.02 and its two-hundred day moving average is $140.16.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the prior year, the business earned ($0.12) EPS. The business’s quarterly revenue was up 63.7% on a year-over-year basis. On average, equities analysts predict that TransMedics Group, Inc. will post 1.22 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $3,267,557.11. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $3,267,557.11. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at $8,180,642.53. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,205 shares of company stock valued at $9,981,907 in the last 90 days. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of TransMedics Group by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after purchasing an additional 23,979 shares in the last quarter. Driehaus Capital Management LLC raised its stake in TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after acquiring an additional 202,867 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in TransMedics Group by 3.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock worth $53,977,000 after acquiring an additional 21,737 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in TransMedics Group by 8.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 297,324 shares of the company’s stock worth $21,985,000 after acquiring an additional 22,223 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. acquired a new stake in TransMedics Group during the 2nd quarter worth $39,862,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.